Research on new and better ways to treat cancer. Covers radiotherapy, targeted microdroplets, nerve-injury protection, drug combinations, and tumor models.
The AI model ARTIMES measures tumor volume rather than diameter, allowing for more accurate predictions of patient survival. This enables physicians to make informed decisions about treatment, potentially leading to improved patient outcomes and reduced healthcare costs.
Researchers at Purdue University have developed a next-generation technology platform designed to dramatically accelerate one of the slowest stages of cancer drug discovery. The platform combines chemical synthesis, biological testing, and mass spectrometry into a single integrated workflow, allowing researchers to generate, evaluate, ...
The Pew Charitable Trusts and the Alexander and Margaret Stewart Trust announced the selection of five early-career scientists to pursue four-year grants in cancer research. The scholars will investigate big questions about cancer development, diagnosis, and treatment.
The Sylvester Cancer Institute has made significant breakthroughs in multiple myeloma treatment with the immunotherapy drug teclistamab, which extends remission and survival rates. Additionally, research has shed light on glioma evolution after treatment and identified genetic markers for aggressive solitary fibrous tumors.
A two-year fixed-duration triplet therapy of pirtobrutinib, venetoclax, and rituximab improves progression free survival for patients with relapsed/refractory CLL compared to standard therapy. Peripheral blood undetectable minimal residual disease rates are higher in patients receiving the triplet therapy.
Researchers developed DNA tetrahedrons with Vitamin E-derived molecules for targeted cancer treatment, enhancing cellular uptake and improving anticancer efficacy. The modification triggered oxidative stress in cancer cells, leading to programmed cell death.
Researchers at UC Irvine have discovered a mechanism that combines DNA damage and inflammatory signaling in tumor cells, potentially improving cancer treatment response. The study found that a combination of PARP inhibitors and TOP1 blockers triggers an 'alarm signal' inside cancer cells, alerting the immune system to eliminate them.
Scientists at VUB mapped healthy pancreas cells down to the cellular level, discovering rare cells with properties similar to aggressive tumour cells. This fundamental discovery may offer opportunities for early detection of pancreatic cancer, currently one of the most difficult diseases to treat.
Rice University has received a $2 million CPRIT award to advance cancer research, including new studies in immunotherapy and ovarian cancer. The funding will support the expansion of the Genetic Design and Engineering Center, which provides a centralized hub for DNA tools used in cancer research.
A recent clinical trial demonstrated that an all-oral drug combination of decitabine-cedazuridine and venetoclax is effective in treating acute myeloid leukemia (AML) in older patients. The regimen showed strong response rates and survival outcomes, with nearly half of patients achieving complete response.
Researchers developed multifunctional metal–organic framework nanoparticles that degrade HK-2, suppress glycolysis, and induce cuproptosis. CHNDs showed stronger anticancer activity than either the HK-2 degrader or the copper nanoplatform alone, disrupting protein homeostasis and cancer energy metabolism.
The study provides new insight into how cells recognize and remove harmful DNA bases using human SMUG1 enzyme. The enzyme removes uracil and related damaged bases from DNA to prevent permanent mutations.
Researchers have tested a new experimental cancer drug called gamitrinib in its first-in-human study. Gamitrinib is designed to target the mitochondria of cancer cells, where it can disrupt their energy systems.
Researchers developed a personalized risk prediction model to identify cancer patients who may struggle with treatment costs, medical debt, and anxiety. The model uses patient information to estimate the likelihood of financial toxicity, balancing detection sensitivity with minimizing false alarms.
Researchers analyzed tumor samples from over a thousand patients and found that TP53 gene mutations can worsen prognosis and reduce effectiveness of targeted therapies. The study suggests incorporating genetic testing into public health services to guide personalized treatment choices.
The study found that adjuvant nivolumab did not improve disease-free survival in patients with resected non–small cell lung cancer. The treatment was also not effective in sensitizing EGFR and ALK alterations.
Researchers at Mount Sinai discovered that focused irradiation can help CAR-T cells survive longer and work more effectively inside tumors. Irradiation turns dendritic cells into a local source of stimulation for CAR-T cells, promoting durable control of advanced lung tumors.
A study published in the New England Journal of Medicine shows an investigational targeted therapy, daraxonrasib, significantly extends overall survival for patients with metastatic pancreatic cancer, reducing death risk by 60%, compared to standard chemotherapy.
A new study shows that targeted cancer drug selpercatinib can significantly reduce the risk of lung cancer returning in patients with a rare genetic subtype. After two years, 92% of patients remained cancer-free, compared to 61% who received a placebo.
A multicenter clinical trial found that implanting collagen tiles during brain surgery improved tumor control and lowered the risk of recurrence by 12.1% compared to current standard of care. Patients treated with tile-based radiation therapy (TBRT) had a median overall survival of 42.5 months, more than double the 17.6 months seen wit...
Two new international studies found that healthy lifestyles can have a protective effect on childhood cancer survivors, reducing the risk of chronic health problems. The studies suggest that physical activity, a healthy weight, and other lifestyle factors can significantly reduce the burden of disease in adulthood.
Research suggests that commonly used anemia medications can inhibit tumor growth and prevent new blood vessel formation, offering a potential dual approach to treating both conditions. The findings open up new possibilities for treating cancer in patients with anemia, who currently face separate treatment goals.
The National Comprehensive Cancer Network (NCCN) has launched a new free service providing weekly email updates on changes to evidence-based guidelines for cancer prevention, screening, treatment, and supportive care. The service aims to keep healthcare providers up-to-date with rapidly evolving evidence-based recommendations.
Researchers discovered that degrading mutant KRAS protein leads to greater lung cancer regression and more durable antitumor responses than conventional inhibitors. The study also identifies resistance mechanisms distinct from those previously described, offering new insights into targeted protein degradation therapies.
Researchers developed targeted platinum-antibody conjugates that effectively enhance tumor immunogenicity and promote anti-tumor immunity. The low-dose platinum delivery strategy showed strong synergy with anti-PD-1 therapy, achieving tumor suppression superior to monotherapy or simple combination treatment.
Researchers at MUSC Hollings Cancer Center have identified a potential way to reduce relapse in medulloblastoma by targeting tumor cells most likely to survive treatment and drive regrowth. The dual-pathway approach, focusing on CK1α, shows promise in preclinical models.
A study by University of Birmingham researchers has identified a new biomarker associated with response to therapy in Ewing Sarcoma and other tumour types. Patients with high aneuploidy scores were significantly more likely to benefit from the treatment, which combines irinotecan and PARP inhibitors.
The MAF Test predicts breast cancer prognosis and helps identify patients who may benefit from treatment. In South Korea, the test could improve survival rates for approximately 34,000 newly diagnosed breast cancer patients each year.
Physicians at Mount Sinai recommend a more patient-centered approach to evaluating skin toxicities in cancer treatments, prioritizing symptom burden and quality of life over treatment type. This new framework could enhance consistency across clinical trials and improve the accuracy of reporting.
Researchers from Mass General Brigham Cancer Institute presented various studies on cancer treatments, including the efficacy of lung cancer drug neladalkib and a psychosocial digital app for patients with multiple myeloma. An electronic frailty index was also used to identify high-risk older adults receiving CAR-T cell therapy.
The National Comprehensive Cancer Network has launched a new version of its Distress Thermometer and Problem List in over 70 languages to screen patients for mental, physical, social, or spiritual distress. The tool aims to enhance cancer care by identifying psychological distress and providing support.
A new cytokine-armored CAR-T cell therapy has been developed to attack aggressive brain tumors in mice while reducing side effects. The approach recruits the body's immune system using IL-12 and DR-18 proteins, strengthening the anti-cancer response and improving tumor control.
A new study by the University of Southampton has found that reusable catheters are just as safe for patients as single-use ones and do not increase the risk of urinary tract infections. The study followed hundreds of patients for a year and discovered that those who tested reusable catheters used 35 per cent fewer antibiotics.
Researchers from The University of Osaka discovered that only a small proportion of CD8 T cells undergo sustained clonal expansion in multiple myeloma immunotherapy, leading to the strongest anti-tumor response. Early immune activity could help predict which cells will become effective cancer fighters.
Researchers found that a common asthma drug can help fight aggressive cancers by blocking the CysLTR1 molecule. The study used mouse models and human tissue samples to demonstrate its potential in treating triple-negative breast cancer and other tough tumors.
An AI technology successfully plans life-saving radiotherapy for cervical and prostate cancers, bridging the workforce gap and enabling more people to be treated. The ARCHERY trial found that the AI technology can achieve international best-practice radiotherapy planning in over 95% of cervical cancer cases.
Researchers found that stereotactic body radiotherapy (SBRT) improved progression-free survival by 15.6 months, compared to 20.6 months without targeted therapy. The treatment also showed no significant impact on quality-of-life measures.
The ASTRO Annual Meeting will take place in Boston from September 26-30, featuring research presentations, keynote addresses, and panel discussions on critical cancer care issues. The meeting aims to foster meaningful conversations about radiation therapy's value in advancing patient care.
Researchers at UT MD Anderson Cancer Center have made significant advancements in cancer care, including the development of a targeted RAS inhibitor therapy for pancreatic cancer and a biomarker of chemotherapy resistance in relapsed lung cancer. The studies also explore the tumor microenvironment of triple-negative breast cancer and i...
A new study aims to make proton therapy available to more patients in Europe by planning five new centres across Romania, Greece, Italy, Northern Ireland, and Poland. Currently, 59% of European cancer patients have access to the treatment, but this can be increased to 87% with strategic location and expansion.
Researchers have identified a hidden mechanism explaining why breast cancer can return years after successful treatment. Slow-growing breast cancer cells can form microscopic tumours that silently tick away in distant organs, evading detection for decades.
At ASCO 2026, City of Hope experts will present research on innovative treatments for various types of cancer. Their findings include the efficacy and safety of immunotherapy combinations, as well as the potential use of CBM588 to enhance immune checkpoint blockade in metastatic renal cell carcinoma.
Researchers have developed nanoparticles that sequentially disable the cancer cell's drug-expulsion mechanism and then release anticancer drugs, combined with photothermal therapy. This approach overcomes multidrug resistance and achieves complete tumor elimination in a mouse model, with no detectable toxicity to normal tissues.
A recent study reveals that combining iNKT cell therapy with antigen-presenting cells activated by a lipid compound triggers effective antitumor immunity. The therapy generates memory-phenotype T cells that can recognize and respond to specific threats, offering a promising personalized approach to cancer treatment.
A NIH-funded study discovered that testosterone may play a key role in limiting brain tumor growth in men by suppressing inflammation and stress hormone production. Analysis of over 1,300 men with glioblastoma found that supplemental testosterone was significantly associated with improved survival rates.
A new CRISPR protein, Cas12a2, has shown potential for killing sick cells while leaving healthy ones untouched. Researchers have tested its effectiveness in destroying cancer cells and virus-infected cells with promising results.
Researchers at UT MD Anderson Cancer Center have made significant advancements in targeted therapy treatments for advanced lung cancer and early-stage classical Hodgkin lymphoma. The studies showcase high response rates with novel combination therapies and a new understanding of how an enzyme affects infertility and cancer progression.
A study published in Cell Reports Medicine found that inhibiting RNase H2 can cause significant damage to DNA and activate the innate immune system to produce signals that attract T cells to attack the tumor. This approach could lead to improved patient outcomes for patients with triple-negative breast cancer.
The ASPIRE trial aims to enroll 1,200 participants with advanced prostate cancer and assess the impact of chemotherapy on overall survival and disease progression. Genetic profiling is included to identify patients who benefit most from intensified treatment.
Researchers at Rutgers University tested the efficacy of Bright IDEAS, a problem-solving skills training intervention, in reducing depression and anxiety symptoms and improving health-related quality of life among young adults with cancer. The study found significant reductions in symptoms and improvements in quality of life compared t...
Researchers from UH, Baylor College of Medicine and MD Anderson Cancer Center propose a new treatment approach for Crohn's disease by targeting the stress signal that fuels inflammation. They found that repurposing two existing cancer medications can promote natural repair and regeneration of the intestinal lining.
Binghamton University Professor L. Nathan Tumey is working on developing new chemical technologies for antibody-drug-conjugates to push the boundaries of what can be accomplished in ADCs. The goal is to awaken tumor-associated immune cells and prevent cancer regrowth.
A new targeted therapy has shown strong results in preclinical studies against aggressive childhood and adult cancers, eliminating tumours and stopping cancer spread. The therapy targets the IL1RAP protein, which is found on cancer cells but largely absent from normal tissues, allowing for precise delivery of treatment.
A new study from Tulane University found that extra sets of chromosomes in tumor cells make them more mobile and likely to engulf neighboring cells. This stress response triggers an abundance of proteins, reprogramming the cells for motility and phagocytosis.
A new treatment using low-dose nivolumab injections into precancerous oral lesions significantly reduced lesion size and risk of cancer progression. The study showed a 60% average reduction in lesion size and complete pathologic response in six patients, with no dose-limiting side effects.
Dr. Aditya Bardia has been elected to the American Society for Clinical Investigation for his outstanding contributions to research and patient care in breast cancer treatment. He is advancing precision medicine therapies through antibody-drug conjugates and liquid biopsy technologies.
Researchers discovered a powerful molecule called miR-181d that weaks tumors and helps the immune system fight back against glioblastoma. The study found that tumors in 'exceptional responders' contain higher levels of miR-181d, which blocks cancer cells' ability to repair DNA damage.
Researchers found that tumor genetics alone did not explain which patients responded to combination therapy, but rather the tumor's immune environment. Patients with active networks of cancer-killing T cells were more likely to benefit from treatment, while those with dense clusters of plasma cells were less likely.
Chemokines regulate immune cell infiltration and local immunity in tumors, and targeting their receptor axis has emerged as a promising therapeutic target in cancer immunotherapy. Chemokine-modulating strategies combining with other immunotherapies have demonstrated considerable synergistic potential.
The Alliance for Clinical Trials in Oncology has several active trials specifically designed to help people with head and neck cancers. Trials include testing high-dose prophylactic gabapentin to prevent opioid use during treatment, as well as immunotherapy with nivolumab and cabozantinib for mucosal melanoma and nasopharyngeal carcino...